Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEK | Q02763 | 3/20 | 0.68 |
| ▸ | BRAF | P15056 | 12/20 | 0.52 |
| ▸ | RAF1 | P04049 | 11/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.52 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.49 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.49 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.49 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15122922 | 0.93 | TEK (0.67) | TEKBRAFRAF1MAPK14HSPB1 | |
| SCHEMBL15123101 | 0.92 | TEK (0.68) | TEKRAF1MAPK14HSPB1 | |
| SCHEMBL15123251 | 0.83 | TEK (0.66) | TEK | |
| SCHEMBL15123237 | 0.82 | TEK (0.66) | TEKMAPK14 | |
| SCHEMBL15123086 | 0.82 | TEK (0.61) | TEK | |
| SCHEMBL15123330 | 0.81 | TEK (0.67) | TEK | |
| SCHEMBL15123725 | 0.81 | TEK (1.00) | TEK | |
| SCHEMBL4019824 | 0.81 | TEK (0.71) | TEKBRAFRAF1MAPK14 | |
| SCHEMBL15122780 | 0.80 | TEK (0.64) | TEKBRAF | |
| SCHEMBL15122924 | 0.80 | TEK (0.64) | TEKBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9394309-B2 | Substituted phenylimidazopyrazoles and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-07-19 | — | — | US | disclosed |
| US-20150005288-A1 | SUBSTITUTED PHENYLIMIDAZOPYRAZOLES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-01-01 | — | — | US | disclosed |
| EP-2807162-A1 | SUBSTITUTED PHENYLIMIDAZOPYRAZOLES AND USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2014-12-03 | — | — | EP | disclosed |
| WO-2013110590-A1 | SUBSTITUTED PHENYLIMIDAZOPYRAZOLES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-08-01 | — | — | WO | disclosed |
| US-20130190290-A1 | Substituted phenylimidazopyrazoles and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005288-A1 | SUBSTITUTED PHENYLIMIDAZOPYRAZOLES AND USE THEREOF | VHL, FLT4, FLT1 | TEK 22/4885BRAF 21/4885RAF1 168/4885 |
| US-20130190290-A1 | Substituted phenylimidazopyrazoles and their use | VHL, FLT4, FLT1 | TEK 29/4885BRAF 19/4885RAF1 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.